![](/img/cover-not-exists.png)
P-105 * Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study
Fuchs, C., Denker, A., Tabernero, J., Van Cutsem, E., Ohtsu, A., Lam, B., Koshiji, M., Bang, Y.- J.Volume:
26
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv233.105
Date:
June, 2015
File:
PDF, 36 KB
2015